Nuclear EGFR-PKM2 axis induces cancer stem cell-like characteristics in irradiation-resistant cells

Cancer Letters

Volumn 422, Issue , 2018, Pages 81-93

  Shi, Ying ^a,b   Liu, Na ^a,b   Lai, Weiwei ^a,b   Yan, Bin ^a,b   Chen, Ling ^a,b   Liu, Shouping ^a,b   Liu, Shuang ^a   Wang, Xiang ^c   Xiao, Desheng ^a   Liu, Xiaoli ^a,b   Mao, Chao ^a,b   Jiang, Yiqun ^a,b   Jia, Jiantao ^d   Liu, Yating ^a,b   Yang, Rui ^a,b   Cao, Ya ^a,b   Tao, Yongguang ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CHANGZHI MEDICAL COLLEGE   (China)

Author keywords

EGFR; Metastasis; PKM2; Radioresistance; Stem like

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HEXOKINASE 1; NUCLEAR PROTEIN; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG; CARRIER PROTEIN; EGFR PROTEIN, HUMAN; MEMBRANE PROTEIN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STEM CELL; CARCINOGENICITY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIORESISTANT CELL LINE; RADIOSENSITIVITY; REGULATORY MECHANISM; A-549 CELL LINE; ANIMAL; CELL NUCLEUS; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

A549 CELLS; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; ERBB RECEPTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; NEOPLASTIC STEM CELLS; PHENOTYPE; RADIATION TOLERANCE; THYROID HORMONES;

EID: 85042848621     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2018.02.028     Document Type: Article

References (48)

1. Bapat, S.A., Evolution of cancer stem cells. Semin. Canc. Biol. 17:3 (2007 Jun), 204–213.
2. Houghton, J., Morozov, A., Smirnova, I., Wang, T.C., Stem cells and cancer. Semin. Canc. Biol. 17:3 (2007 Jun), 191–203.
3. Takaishi, S., Okumura, T., Tu, S., Wang, S.S., Shibata, W., Vigneshwaran, R., et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cell. 27:5 (2009 May), 1006–1020.
4. Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., et al. Identification of a cancer stem cell in human brain tumors. Canc. Res. 63:18 (2003 Sep 15), 5821–5828.
5. Patrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:12 (2006 Mar 16), 1696–1708.
6. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., Clarke, M.F., Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100:7 (2003 Apr 01), 3983–3988.
7. Dalerba, P., Dylla, S.J., Park, I.K., Liu, R., Wang, X., Cho, R.W., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 104:24 (2007 Jun 12), 10158–10163.
8. O'Brien, C.A., Pollett, A., Gallinger, S., Dick, J.E., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:7123 (2007 Jan 04), 106–110.
9. Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., et al. Identification of pancreatic cancer stem cells. Canc. Res. 67:3 (2007 Feb 01), 1030–1037.
10. Cojoc, M., Peitzsch, C., Kurth, I., Trautmann, F., Kunz-Schughart, L.A., Telegeev, G.D., et al. Aldehyde dehydrogenase is regulated by beta-catenin/TCF and promotes radioresistance in prostate cancer progenitor cells. Canc. Res. 75:7 (2015 Apr 01), 1482–1494.
11. Kurth, I., Hein, L., Mabert, K., Peitzsch, C., Koi, L., Cojoc, M., et al. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. Oncotarget 6:33 (2015 Oct 27), 34494–34509.
12. Skvortsova, I., Debbage, P., Kumar, V., Skvortsov, S., Radiation resistance: cancer stem cells (CSCs) and their enigmatic pro-survival signaling. Semin. Canc. Biol. 35 (2015 Dec), 39–44.
13. Brunner, T.B., Kunz-Schughart, L.A., Grosse-Gehling, P., Baumann, M., Cancer stem cells as a predictive factor in radiotherapy. Semin. Radiat. Oncol. 22:2 (2012 Apr), 151–174.
14. Yarden, Y., Sliwkowski, M.X., Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:2 (2001 Feb), 127–137.
15. Nyati, M.K., Morgan, M.A., Feng, F.Y., Lawrence, T.S., Integration of EGFR inhibitors with radiochemotherapy. Nat. Rev. Canc. 6:11 (2006 Nov), 876–885.
16. Liccardi, G., Hartley, J.A., Hochhauser, D., EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Canc. Res. 71:3 (2011 Feb 01), 1103–1114.
17. Bora-Singhal, N., Perumal, D., Nguyen, J., Chellappan, S., Gli1-Mediated regulation of Sox2 facilitates self-renewal of stem-like cells and confers resistance to EGFR inhibitors in non-small cell lung cancer. Neoplasia 17:7 (2015 Jul), 538–551.
18. Arai, C., Yoshizaki, K., Miyazaki, K., Saito, K., Yamada, A., Han, X., et al. Nephronectin plays critical roles in Sox2 expression and proliferation in dental epithelial stem cells via EGF-like repeat domains. Sci. Rep., 7, 2017 Mar 27 45181.
19. Xu, H., Wu, K., Tian, Y., Liu, Q., Han, N., Yuan, X., et al. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int. J. Oncol. 49:4 (2016 Oct), 1343–1350.
20. Jang, J.W., Song, Y., Kim, S.H., Kim, J.S., Kim, K.M., Choi, E.K., et al. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. Canc. Lett. 389 (2017 Mar 28), 1–10.
21. Kobayashi, I., Takahashi, F., Nurwidya, F., Nara, T., Hashimoto, M., Murakami, A., et al. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. Biochem. Biophys. Res. Commun. 473:1 (2016 Apr 22), 125–132.
22. Codony-Servat, C., Codony-Servat, J., Karachaliou, N., Molina, M.A., Chaib, I., Ramirez, J.L., et al. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget 8:29 (2017 Jul 18), 47305–47316.
23. Israelsen, W.J., Vander Heiden, M.G., Pyruvate kinase: function, regulation and role in cancer. Semin. Cell Dev. Biol. 43 (2015 Jul), 43–51.
24. He, Y., Gao, M., Cao, Y., Tang, H., Liu, S., Tao, Y., Nuclear localization of metabolic enzymes in immunity and metastasis. Biochim. Biophys. Acta 1868:2 (2017 Jul 27), 359–371.
25. Gu, Z., Xia, J., Xu, H., Frech, I., Tricot, G., Zhan, F., NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase. J. Hematol. Oncol., 10(1), 2017 Jan 13, 17.
26. Chen, L., Shi, Y., Liu, S., Cao, Y., Wang, X., Tao, Y., PKM2: the thread linking energy metabolism reprogramming with epigenetics in cancer. Int. J. Mol. Sci. 15:7 (2014 Jun 26), 11435–11445.
27. Yang, Y.C., Cheng, T.Y., Huang, S.M., Su, C.Y., Yang, P.W., Lee, J.M., et al. Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association. Oncogene 35:26 (2016 Jun 30), 3387–3398.
28. Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480:7375 (2011 Dec 01), 118–122.
29. Lee, Y.S., Oh, J.H., Yoon, S., Kwon, M.S., Song, C.W., Kim, K.H., et al. Differential gene expression profiles of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 77:3 (2010 Jul 01), 858–866.
30. Shi, Y., Tao, Y., Jiang, Y., Xu, Y., Yan, B., Chen, X., et al. Nuclear epidermal growth factor receptor interacts with transcriptional intermediary factor 2 to activate cyclin D1 gene expression triggered by the oncoprotein latent membrane protein 1. Carcinogenesis 33:8 (2012 Aug), 1468–1478.
31. Xu, Y., Shi, Y., Yuan, Q., Liu, X., Yan, B., Chen, L., et al. Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. J. Exp. Clin. Canc. Res.: CR (Clim. Res.), 32, 2013 Nov 13, 90.
32. Wang, R., Shi, Y., Chen, L., Jiang, Y., Mao, C., Yan, B., et al. The ratio of FoxA1 to FoxA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH. Sci. Rep., 5, 2015 Dec 11 17826.
33. Jiang, Y., Yan, B., Lai, W., Shi, Y., Xiao, D., Jia, J., et al. Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8. Oncogene 34:50 (2015 Dec 10), 6079–6091.
34. Goodell, M.A., McKinney-Freeman, S., Camargo, F.D., Isolation and characterization of side population cells. Meth. Mol. Biol. 290 (2005), 343–352.
35. Arteaga, C.L., EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J. Clin. Oncol. 21:23 Suppl (2003 Dec 1), 289s–291s.
36. Lo, H.W., Hung, M.C., Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br. J. Canc. 94:2 (2006 Jan 30), 184–188.
37. Lo, H.W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.F., Hung, M.C., Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Canc. Res. 65:1 (2005 Jan 1), 338–348.
38. Hung, L.Y., Tseng, J.T., Lee, Y.C., Xia, W., Wang, Y.N., Wu, M.L., et al. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res. 36:13 (2008 Aug), 4337–4351.
39. Carmena, M., Earnshaw, W.C., The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 4:11 (2003 Nov), 842–854.
40. Huo, L., Wang, Y.N., Xia, W., Hsu, S.C., Lai, C.C., Li, L.Y., et al. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc. Natl. Acad. Sci. U. S. A. 107:37 (2010 Sep 14), 16125–16130.
41. Li, N., Feng, L., Liu, H., Wang, J., Kasembeli, M., Tran, M.K., et al. PARP inhibition suppresses growth of EGFR-mutant cancers by targeting nuclear PKM2. Cell Rep. 15:4 (2016), 843–856.
42. Wang, H.-J., Hsieh, Y.-J., Cheng, W.-C., Lin, C.-P., Lin, Y-s, Yang, S.-F., et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α–mediated glucose metabolism. Proc. Natl. Acad. Sci. Unit. States Am. 111:1 (2014), 279–284.
43. Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150:4 (2012 Aug 17), 685–696.
44. Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14:12 (2012 Dec), 1295–1304.
45. Baumann, M., Krause, M., Hill, R., Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Canc. 8:7 (2008 Jul), 545–554.
46. Xu, J., Deng, X., Tang, M., Li, L., Xiao, L., Yang, L., et al. Tyrosylprotein sulfotransferase-1 and tyrosine sulfation of chemokine receptor 4 are induced by Epstein-Barr virus encoded latent membrane protein 1 and associated with the metastatic potential of human nasopharyngeal carcinoma. PLoS One, 8(3), 2013, e56114.
47. Mandl, M., Lieberum, M., Dunst, J., Depping, R., The expression level of the transcription factor Aryl hydrocarbon receptor nuclear translocator (ARNT) determines cellular survival after radiation treatment. Radiat. Oncol., 10, 2015, 229.
48. He, X., Yan, B., Liu, S., Jia, J., Lai, W., Xin, X., et al. Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. Canc. Res. 76:19 (2016 Oct 01), 5743–5755.